Literature DB >> 22689318

Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis.

Willem E van Spil1, K Wiepke Drossaers-Bakker, Floris P J G Lafeber.   

Abstract

OBJECTIVE: CTX-II (C-terminal telopeptide of type II collagen) has been put forward as a marker of collagen type II degradation being part of osteoarthritis. In this study, the authors describe similarities between CTX-II and bone markers arguing against CTX-II as a marker of (solely) cartilage degradation.
METHODS: uCTX-II, the bone markers uCTX-I, uNTX-I, sPINP, and sOC (C-terminal and N-terminal telopeptides of collagen I, aminoterminal propeptide of type I procollagen, and osteocalcin, respectively), and other (candidate) cartilage markers sCOMP, sCS846, and sPIIANP (cartilage oligomeric matrix protein, chondroitin sulphate 846 and type IIA collagen N-propeptide, respectively) were assessed by ELISA in CHECK (Cohort Hip and Cohort Knee), a cohort of 1002 individuals with early pain and/or stiffness in knee and/or hip.
RESULTS: uCTX-II was more strongly associated with the bone markers than with the other cartilage markers, while the other cartilage markers were not so strongly associated with the bone markers. Moreover, both uCTX-II and bone markers but not the other cartilage markers showed an abrupt menopausal shift in women aged 48-53 years, also when adjusted for age and BMI.
CONCLUSION: The similarities between uCTX-II and bone markers could be attributable to a link between cartilage and bone metabolism through metabolic and biomechanical mechanisms. However, other cartilage markers were hardly associated with uCTX-II and did not show such evident associations with bone markers. uCTX-II has unique relations with bone markers as compared to other cartilage markers and might reflect bone rather than cartilage metabolism. More thorough molecular validation of uCTX-II is required.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689318     DOI: 10.1136/annrheumdis-2011-201177

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  18 in total

Review 1.  Osteoarthritis and osteoporosis: what is the overlap?

Authors:  Irene E M Bultink; Willem F Lems
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

Review 2.  The evolving role of biomarkers for osteoarthritis.

Authors:  Muneaki Ishijima; Haruka Kaneko; Kazuo Kaneko
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-08       Impact factor: 5.346

3.  Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial.

Authors:  Takashi Nishii; Satoru Tamura; Toshiyuki Shiomi; Hideki Yoshikawa; Nobuhiko Sugano
Journal:  Clin Rheumatol       Date:  2013-07-24       Impact factor: 2.980

4.  Alpha C-telopeptide of type I collagen is associated with subchondral bone turnover and predicts progression of joint space narrowing and osteophytes in osteoarthritis.

Authors:  Janet L Huebner; Anne C Bay-Jensen; Kim M Huffman; Yi He; Diana J Leeming; Gary E McDaniel; Morten A Karsdal; Virginia B Kraus
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

5.  Association Between Biochemical Markers of Bone Turnover and Bone Changes on Imaging: Data From the Osteoarthritis Initiative.

Authors:  Leticia A Deveza; Virginia B Kraus; Jamie E Collins; Ali Guermazi; Frank W Roemer; Michael Bowes; Michael C Nevitt; Christoph Ladel; David J Hunter
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-07-10       Impact factor: 4.794

6.  The effects of a calcium-rich pre-exercise meal on biomarkers of calcium homeostasis in competitive female cyclists: a randomised crossover trial.

Authors:  Eric C Haakonssen; Megan L Ross; Emma J Knight; Louise E Cato; Alisa Nana; Anita E Wluka; Flavia M Cicuttini; Bing H Wang; David G Jenkins; Louise M Burke
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

7.  Relationships amongst osteoarthritis biomarkers, dynamic knee joint load, and exercise: results from a randomized controlled pilot study.

Authors:  Michael A Hunt; Courtney L Pollock; Virginia Byers Kraus; Tore Saxne; Sue Peters; Janet L Huebner; Eric C Sayre; Jolanda Cibere
Journal:  BMC Musculoskelet Disord       Date:  2013-03-27       Impact factor: 2.362

8.  Republished: Value of biomarkers in osteoarthritis: current status and perspectives.

Authors:  M Lotz; J Martel-Pelletier; C Christiansen; M-L Brandi; O Bruyère; R Chapurlat; J Collette; C Cooper; G Giacovelli; J A Kanis; M A Karsdal; V Kraus; W F Lems; I Meulenbelt; J-P Pelletier; J-P Raynauld; S Reiter-Niesert; R Rizzoli; L J Sandell; W E Van Spil; J-Y Reginster
Journal:  Postgrad Med J       Date:  2014-03       Impact factor: 2.401

Review 9.  Value of biomarkers in osteoarthritis: current status and perspectives.

Authors:  M Lotz; J Martel-Pelletier; C Christiansen; M-L Brandi; O Bruyère; R Chapurlat; J Collette; C Cooper; G Giacovelli; J A Kanis; M A Karsdal; V Kraus; W F Lems; I Meulenbelt; J-P Pelletier; J-P Raynauld; S Reiter-Niesert; R Rizzoli; L J Sandell; W E Van Spil; J-Y Reginster
Journal:  Ann Rheum Dis       Date:  2013-07-29       Impact factor: 19.103

10.  Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.

Authors:  Tsutomu Takeuchi; Yoshiya Tanaka; Naoki Ishiguro; Hisashi Yamanaka; Toshiyuki Yoneda; Takeshi Ohira; Naoki Okubo; Harry K Genant; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2015-11-19       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.